Allovir Inc

ALVR11 Dec 2024
Healthcare
$0.51
0.00 (-0.16%)
Lowest Today
$0.51
Highest Today
$0.51
Today’s Open
$0.51
Prev. Close
$0.51
52 Week High
$2.49
52 Week Low
$0.48
To Invest in Allovir Inc

Allovir Inc

Healthcare
ALVR11 Dec 2024
0.00 (-0.16%)
1M
3M
6M
1Y
5Y
Low
$0.51
Day’s Range
High
$0.51
0.51
52 Week Low
$0.48
52-Week Range
52 Week High
$2.48
0.48
1 Day
-
1 Week
-2.79%
1 month return
-27.64%
3 month return
-30.48%
6 month return
-34.56%
1 Year return
-76.26%
3 Years return
-96.73%
5 Years return
-
10 Years return
-
Institutional Holdings
EcoR1 Capital, LLC
9.78
Octagon Capital Advisors LP
9.7
Millennium Management LLC
2.84
Vanguard Group Inc
2.29
Redmile Group, LLC
1.65
Vanguard Total Stock Mkt Idx Inv
1.53
Acuitas Investments, LLC
0.93

Market Status

Fundamentals
Market Cap
85.25 mln
PB Ratio
0.48
PE Ratio
0
Enterprise Value
-63.74 mln
Total Assets
190.8 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Organisation
Allovir Inc
Employees
8
Industry
Biotechnology
CEO
Dr. Diana M. Brainard M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step